Fast-Tracking Biosimilars: South Korea to Waive Phase 3 Clinical Trials Under New Guidelines
South Korean regulators have revised requirements to significantly reduce the time and financial burden of biosimilar development.
Search results for "new drug development"
Landmark Biotech Deal: Celltrion Acquires Autoimmune Disease Antibody Tech from Catholic University of Korea
A research team led by Kim Wan-wook at the Catholic University of Korea College of Medicine has successfully transferred a novel antibody technology...
Daewoong Pharmaceutical’s Nabota Hits 1 Trillion Won in Cumulative Sales 12 Years Post-Launch
Daewoong Pharmaceutical announced on the 13th that its flagship botulinum toxin product, Nabota, surpassed 1 trillion...
AI Cancer Gene Analysis and 810 Billion-Won Tech Export Lead South Korea's Top 30 Health Care R&D Achievements
The Ministry of Health and Welfare and the Korea Health Industry Development Institute announced on the 8th that they...
Novartis to Buy UK Biotech Myricx for Up to $1.5 Billion, Boosting ADC Portfolio
Novartis is significantly expanding its oncology portfolio after securing an antibody-drug conjugate technology...
Qurient’s Mocaciclib Opens New Combination Frontiers for Hard-to-Treat Breast Cancer
Qurient announced on June 29 that it presented key clinical data highlighting the mechanistic advantages of its...
For Cancer Caregivers, the Dread of Future Costs Harms Health 8 Times More Than Actual Bills
For many families navigating a parent or loved one’s cancer diagnosis, sleepless nights become the new normal.
Air Pollution Threatens Skin Health: Fine Dust Increases Psoriasis Risk by Up to 27%
A large-scale study has found that fine dust can severely damage skin health, expanding the known dangers of air...
Diabetes Drug Repurposed: Evogliptin Shows Promise in Preventing Disfiguring Burn Scars
Burn survivors frequently face a distressing secondary complication known as hypertrophic scarring, where the skin...
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’
The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological...